Product status
Which product lane are you being asked to enter?
The label “peptide” is not enough. Approval, compounding and research sales are different routes with different checks.
Approved route
What does FDA-approved mean here?
As of September 2026, the medicines semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) had FDA-approved products for type 2 diabetes, weight management or other specific uses.
A look-alike or compounded product that says it contains the same ingredient is not automatically the approved product.
Compounded route
Can a compounded medicine be real care?
Compounding can address a patient need that an approved product cannot, yet the resulting medicine has no FDA approval and receives no FDA review before marketing.
Federal law limits pharmacies from routinely making near-copies of medicines already available, unless a prescriber identifies a change that makes a significant difference for one patient.
As of September 2026, semaglutide and tirzepatide were not on the FDA drug shortage list.
Research route
Does “research use only” make a vial legitimate care?
FDA warning letters say the answer is no when the product is really marketed for human use.
Retatrutide is an experimental medicine being studied for weight management. As of September 2026, it was not FDA-approved, and the FDA stated that it could not be used in compounding under federal law.
Brief source note
FDA records show which products are approved, current compounding limits and warnings about unapproved weight medicines.
What is the fastest way to sort the lanes?
Ask for the exact generic name, the maker or the pharmacy or facility that made it to order, the approved use if one exists, and the reason a compounded version is being considered.